MS HB1268

Allows pharmacists to substitute FDA-approved interchangeable biosimilar products for prescribed biological products without prescriber intervention

Substitution permitted only if prescriber has not expressly prohibited product selection in writing, verbally, or electronically

Requires pharmacist to notify patient and obtain consent before substitution

Pharmacist must notify prescriber within 10 days of dispensing by recording in shared electronic health records system or via facsimile, telephone, email, or other means, with written records retained for at least 10 years

State Board of Pharmacy must maintain a public website list of biosimilar products determined to be interchangeable by the FDA; effective July 1, 2014